Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2012 June;37(2) > Minerva Endocrinologica 2012 June;37(2):117-32

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

ENDOCRINE ONCOLOGY  


Minerva Endocrinologica 2012 June;37(2):117-32

language: English

Endometrial carcinoma tumorigenesis and pharmacotherapy research

Shu J. 1, Fang S. 2, Teichman P. G. 3, Xing L. 1, Huang H. 4

1 School of Medicine, Zhejiang University, Hangzhou, China;
2 Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China;
3 Genesys Regional Medical Center, Michigan State University, Grand Blanc, MI, USA;
4 Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China


PDF  


Endometrial carcinoma is the common malignant tumor of the female genital tract, and its incidence is increasing. Two different clinicopathological subtypes are recognized based on epidemiology, genetic carcinogenesis and clinical behavior. Understanding and identifying molecular biology and genetics is essential to the development of novel therapies. This article reviews the current understanding of its risk factors, recent conceptions on its tumorigenesis and advances on its drug therapies.

top of page

Publication History

Cite this article as

Corresponding author e-mail

huanghefg@hotmail.com